Granted Patent B2

US 12,290,434 · App. 18/301,569 · Granted May 6, 2025

Inventors: Gary N. Wortz (Nicholasville, KY); Rick William Ifland (Versailles, KY)

Assignee: Omega Ophthalmics LLC

A61F2/1613A61F2/15A61F2/1601A61F2/1618A61F2/1624A61F2/1648A61F2/1694A61F2/1627A61F2002/1681A61F2002/16901

Abstract

Claims (31)

1. A prosthetic capsular device configured to be inserted in a natural capsular bag of an eye after removal of a lens, the device comprising:

a housing structure capable of containing a drug eluting device, the housing structure comprising:

an anterior portion comprising:

an anterior opening, wherein the anterior opening is capable of allowing at least one of insertion, removal, or replacement of the drug eluting device, wherein the anterior opening is surrounded by an anterior wall defining a first capsular-engaging surface, and

an anterior lateral sidewall extending from the anterior opening;

a posterior portion comprising:

a posterior opening, wherein the posterior opening is capable of allowing at least one of insertion, removal, or replacement of the drug eluting device, and wherein the posterior opening is surrounded by a posterior wall defining a second capsular-engaging surface, and

a posterior lateral sidewall extending from the posterior opening; and

a lateral portion interposed between the anterior portion and the posterior portion, wherein the lateral portion comprises a central lateral sidewall that protrudes radially beyond the anterior lateral sidewall and the posterior lateral sidewall,

wherein the anterior lateral sidewall, central lateral sidewall, and posterior lateral sidewall form a lateral side of the housing structure,

wherein the central lateral sidewall comprises an exterior surface comprising a rounded bulge, the rounded bulge extending radially beyond the anterior lateral sidewall and the posterior lateral sidewall, and

wherein the central lateral sidewall comprises an interior surface comprising the structure.

2. The prosthetic capsular device of claim 1 , wherein the central lateral sidewall comprises a first straight portion adjacent to the anterior lateral sidewall and a second straight portion adjacent to the posterior lateral sidewall.

3. The prosthetic capsular device of claim 2 , wherein the first straight portion extends from the anterior lateral sidewall, and wherein the second straight portion extends from the posterior lateral sidewall.

4. The prosthetic capsular device of claim 1 , wherein the housing structure further comprises a central cavity, the central cavity at least partially defined by the anterior lateral sidewall, the posterior lateral sidewall, and the central lateral sidewall.

5. The prosthetic capsular device of claim 1 , wherein the drug eluting device is capable of being inserted separately from the housing structure into the natural capsular bag without being attached to the housing structure.

6. The prosthetic capsular device of claim 1 , wherein the prosthetic capsular device comprises at least one of silicone, hydrogel, collamer, acrylic, or an acrylic derivative.

7. The prosthetic capsular device of claim 1 , wherein the prosthetic capsular device is self-expandable upon insertion in the natural capsular bag.

8. The prosthetic capsular device of claim 1 , wherein the prosthetic capsular device is deformable for insertion in the natural capsular bag.

9. The prosthetic capsular device of claim 1 , wherein the housing structure is symmetrical over a plane at a midpoint of the lateral portion between the anterior portion and the posterior portion.

10. The prosthetic capsular device of claim 1 , wherein the prosthetic capsular device is sized and scaled to accommodate a size of the eye.

11. The prosthetic device of claim 1 , wherein at least one exterior surface of the housing structure comprises a roughened or opacified surface.

12. The prosthetic device of claim 1 , wherein the drug eluting device comprises a slow-release injectable.

13. The prosthetic device of claim 12 , wherein the slow-release injectable comprises an anti-VEGF injectable.

14. The prosthetic device of claim 12 , wherein the slow-release injectable comprises an aflibercept.

15. The prosthetic device of claim 12 , wherein the slow-release injectable comprises anti-VEGF produced from cells.

16. The prosthetic device of claim 1 , wherein the anterior opening and/or the posterior opening is configured to allow a medicament of the drug eluting device to access a posterior capsule of the eye.

17. The prosthetic device of claim 1 , wherein the housing structure comprises a flexible or elastic material.

18. The prosthetic device of claim 1 , wherein the housing structure is foldable or collapsible for implantation to the eye.

19. The prosthetic device of claim 1 , wherein the lateral portion comprises a concave shape.

20. The prosthetic device of claim 1 , wherein the housing structure is molded from a single piece of material.

Assignments (1)

Continuity (8)

References Cited (400)